Table 4.

Follow-up feedbacks of patients after nebulization treatment

	Days from the onset of nebulization treatment	Clinical Symptoms	COVID-19 antibody test	Lymphocyte count	Alanine aminotransferase (ALT) (U/L)	Creatinine (Cr) (μmol/L)	Chest CT images
Patient 1	Day 20	Denied	IgM ( −), IgG ( −)	2.29 × 109/L	N/A	N/A	Obvious absorption of infiltration at both lobes compared with the day of symptom onset
	Day 36	Denied	N/A	N/A	N/A	N/A	Slight absorption compared with Day 20
Patient 2	Day 41	Denied	IgM ( −), IgG ( +)	2.14 × 109/L	45	53	Partial absorption of infiltration compared with the day of symptom onset
Patient 3	Day 22	Denied	N/A	N/A	N/A	N/A	Normal
	Day 59	Denied	N/A	3.72 × 109/L	9	63	Normal
Patient 4	Day 17	Mild cough	N/A	N/A	N/A	N/A	Infiltration at both lobes, similar to the day of symptom onset
	Day 43	Denied	N/A	N/A	N/A	N/A	Infiltration at both lobes, similar to Day 17
Patient 5	Day 36	Denied	IgM ( −), IgG ( +)	2.52 × 109/L	20	55	Slight absorption compared with the day of symptom onset
Patient 6	Day 24	Mild cough	N/A	N/A	N/A	49	N/A
Patient 7	Day 28	Denied	IgM ( −), IgG ( +)	1.82 × 109/L	10	50	Obvious absorption of infiltration at both lobes compared with Day 2
	Day 52	Denied	N/A	1.97 × 109/L	N/A	N/A	Slight absorption compared with Day 28